New drug combo shows promise in shrinking aggressive breast tumors before surgery
NCT ID NCT02530489
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of chemotherapy (nab-paclitaxel) and immunotherapy (atezolizumab) given before surgery to women with triple-negative breast cancer. The goal was to shrink tumors and reduce the amount of breast tissue that needs to be removed. The trial involved 37 participants and looked at how much cancer remained at the time of surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fasting during chemo: a new way to boost treatment?
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a vaccine train the immune system to hunt down hidden breast cancer cells?
- Could a common cholesterol drug boost breast cancer treatment?
- Gene test could guide breast cancer treatment to boost survival
- Vaccine aims to block return of aggressive breast cancer